IP Library Granted Patent US 11,559,482
Granted Patent B2
US 11,559,482 · App. 13/387,971 · Granted Jan 24, 2023

Biodegradable polyethylene glycol based water-insoluble hydrogels

Inventors: Harald Rau (Heidelberg, DE); Ulrich Hersel (Heidelberg, DE); Mathias Krusch (Hirschhorn, DE); Dirk Vetter (Heidelberg, DE); Tobias Voigt (Heidelberg, DE)
Assignee: Ascendis Pharma A/S
A61K9/0024A61K47/10A61K47/60A61K47/6903C08J3/075
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,559,482
App. No.
13/387,971
Granted
Jan 24, 2023
Kind
B2
Abstract

The present invention relates to biodegradable polyethylene glycol based water-insoluble hydrogels comprising backbone moieties which are interconnected by hydrolytically degradable bonds, the backbone moieties further comprising reactive functional groups, wherein the water-insoluble hydrogel is further characterized in that the ratio between the time period for the complete degradation of the hydrogel by hydrolysis of the degradable bonds into water-soluble degradation products comprising one or more backbone moieties and the time period for the release of the first 10 mol-% of water-soluble degradation products comprising one or more backbone moieties based on the total amount of backbone moieties in the hydrogel is greater than 1 and equal to or less than 2. The invention further relates to conjugates of such hydrogels with ligands or ligating groups, prodrugs and pharmaceutical compositions as well as their use in a medicament.

Claims (39)

1. A biodegradable poly(ethylene glycol) based water-insoluble hydrogel consisting of:

backbone moieties which are interconnected by hydrolytically degradable bonds;

wherein the backbone moieties are linked together through crosslinker moieties, each crosslinker moiety being terminated by at least two of the hydrolytically degradable bonds; and

wherein each backbone moiety has a molecular weight in the range of from 1 kDa to 20 kDa and has the structure:

C*(A-Hyp) x

wherein:

C* is a branching core consisting of in bound form an oligoalcohol or polyalcohol;

A is a poly(ethylene glycol) based polymeric chain;

Hyp is a hyperbranched dendritic moiety consisting of:

reactive functional groups;

degradable interconnected functional groups, each degradable interconnected functional group being connected to one of the crosslinker moieties and consisting of one of the hydrolytically degradable bonds; and

lysine in bound form; and

x is an integer of from 3 to 16, so that each backbone moiety has at least 6 reactive functional groups and 6 degradable interconnected functional groups;

wherein the hydrogel is in the form of microparticles; and

wherein the hydrolytically degradable bonds include at least one bond selected from the group consisting of acetals, carboxylic anhydrides, esters, imines, hydrazones, maleamic acid amides, ortho esters, phosphamides, phosphoesters, phosphosilyl esters, silyl esters, sulfonic esters, aromatic carbamates, and combinations thereof.

2. The biodegradable hydrogel of claim 1 ;

wherein each crosslinker moiety has a molecular weight in the range of from 0.5 kDa to 5 kDa; and

wherein each crosslinker moiety is PEG based.

3. The biodegradable hydrogel of claim 1 ;

wherein each backbone moiety comprises in sum at least 16 interconnected biodegradable and reactive functional groups.

4. A conjugate comprising:

the hydrogel of claim 1 ;

wherein the hydrogel additionally carries permanent linkages to spacer molecules or blocking groups or combinations thereof.

5. A conjugate comprising:

the hydrogel of claim 1 ;

wherein the hydrogel additionally carries permanent linkages to ligands or chelating groups.

6. A carrier-linked prodrug comprising:

the biodegradable hydrogel of claim 1 as carrier;

wherein a number of permanent linkages of the backbone moieties exist, each with a transient prodrug linker L to which a biologically active moiety D is covalently attached.

7. The carrier-linked prodrug of claim 6 ;

wherein the transient linkage between D and L is a carbamate, carbonate, amide, or ester linkage.

8. The carrier-linked prodrug of claim 6 ;

wherein the transient prodrug linker L comprises a moiety L 1 , which is substituted with a moiety L 2 ; and

wherein L 2 is bound to a carrier group Z, which is the hydrogel.

9. The carrier-linked prodrug of claim 8 ;

wherein L 2 is attached to Z via a terminal group having the following structure:

wherein the dashed lines indicate the attachment to L 2 and Z, respectively.

10. The hydrogel of claim 1 ;

wherein the microparticles are obtained by comminution by a mechanical process.

Assignments (6)
CORRECTIVE ASSIGNMENT TO CORRECT THE THE RECEIVING PARTY STATE/COUNTRY PREVIOUSLY RECORDED AT REEL: 063695 FRAME: 0585. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Jun 13, 2023
From: ASCENDIS PHARMA GMBH
To: ASCENDIS PHARMA A/S
Reel/Frame 063988/0288 →
CORRECTIVE ASSIGNMENT TO CORRECT THE RECORD BY REPLACING THE PREVIOUSLY RECORDED ASSIGNMENT PREVIOUSLY RECORDED ON REEL 046571 FRAME 0787. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded May 18, 2023
From: RAU, HARALD, DR.; HERSEL, ULRICH, DR.; KRUSCH, MATHIAS; VETTER, DIRK, DR.; VOIGT, TOBIAS, DR.
To: ASCENDIS PHARMA GMBH
Reel/Frame 063691/0840 →
CORRECTIVE ASSIGNMENT TO CORRECT THE RECEIVING PARTY DATA PREVIOUSLY RECORDED AT REEL: 046571 FRAME: 0881. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded May 18, 2023
From: ASCENDIS PHARMA GMBH
To: ASCENDIS PHARMA A/S
Reel/Frame 063695/0585 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 7, 2018
From: RAU, HARALD, DR.; HERSEL, ULRICH, DR.; KRUSCH, MATHIAS; VETTER, DIRK, DR.; VOIGT, TOBIAS, DR.
To: ASCENDIS PHARMA GMBH
Reel/Frame 046571/0787 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 7, 2018
From: ASCENDIS PHARMA GMBH
To: ASCENDIS PHARMA A/S
Reel/Frame 046571/0881 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 6, 2012
From: RAU, HARALD, DR.; HERSEL, ULRICH, DR.; KRUSCH, MATHIAS; VETTER, DIRK, DR.; VOIGT, TOBIAS, DR.
To: ASCENDIS PHARMA AS
Reel/Frame 027812/0838 →
Priority Claims (2)
EP 09167026 · Jul 31, 2009 · regional
EP 09172339 · Oct 6, 2009 · regional
Continuity (1)
Related Publication 20120156259A1 · Jun 21, 2012